Highlights

  • Mesoblast Limited (ASX:MSB) rose 6.25% to A$2.38 on 13 July 2026, at a market capitalisation of about A$2.9 billion.
  • The rally followed a 10 July 2026 announcement that Ryoncil delivered preliminary net revenue of about US$36 million for the June 2026 quarter and about US$115 million for its first full year on the US market.
  • Ryoncil (remestemcel-L) is the first FDA-approved mesenchymal stromal cell therapy, approved in December 2024 for paediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD).
  • Mesoblast is pursuing a label extension to adult SR-aGvHD and advancing Revascor in heart failure and a Phase 3 program in chronic low back pain.
  • Investors may watch adult-GvHD progress, the Revascor BLA pathway, chronic low back pain Phase 3 data, and cash burn against a cash balance reported at about US$130 million at 31 December 2025.

A commercial cell-therapy story reignites

Mesoblast Limited (ASX:MSB), the Melbourne-based cell-therapy developer, jumped 6.25% to A$2.38, at the time of writing on 13 July 2026. The gain lifted its market capitalisation to about A$2.9 billion and put one of the ASX's longest-running biotechnology names back in focus.

The surge is notable because Mesoblast spent much of its two-decade history as a clinical-stage company burning cash in pursuit of approval. That changed in December 2024, when Ryoncil became the first mesenchymal stromal cell (MSC) therapy approved by the US Food and Drug Administration. The 13 July 2026 move followed hard data confirming the commercial launch is exceeding early expectations — a genuine inflection for a stock long defined by promise rather than sales. The question now is whether Mesoblast can convert a strong first-year launch into durable, diversified revenue.

What happened to Mesoblast shares?

On 13 July 2026, Mesoblast shares rose 6.25% to A$2.38, among the session's stronger performers, extending momentum triggered days earlier by the company's fourth-quarter revenue update. Mesoblast has historically been a volatile stock, trading below A$2 at points in the prior year before recovering as Ryoncil's commercial trajectory became clearer. The gain reflects investors rewarding tangible revenue delivery. Snapshot figures are delayed and may have changed.

Was there a verified catalyst?

Yes. On 10 July 2026, Mesoblast announced that Ryoncil delivered preliminary net revenue of about US$36 million for the fourth quarter ended 30 June 2026, taking full-year net revenue to about US$115 million for the product's first full year on the US market. The company noted these figures were preliminary and unaudited. Chief Executive Dr Silviu Itescu said uptake had exceeded initial projections, with continued growth anticipated across major US paediatric centres. This is a clearly identifiable, verified catalyst — revenue that beat market expectations, arriving just before the snapshot date — and the 6.25% gain is consistent with the market digesting that result. A single quarter's momentum is not a guarantee of future performance.

What does Mesoblast Limited (ASX:MSB) do?

Mesoblast is a regenerative-medicine company that develops allogeneic (off-the-shelf) cellular medicines based on mesenchymal stromal cells derived from healthy-donor bone marrow. These cells are expanded using proprietary manufacturing to create therapies aimed at modulating inflammation and immune responses. Its lead product, Ryoncil (remestemcel-L), treats steroid-refractory acute graft-versus-host disease, a serious and often life-threatening complication of allogeneic bone-marrow transplantation. Mesoblast also maintains a pipeline spanning cardiovascular disease and chronic inflammatory conditions, leveraging the same MSC platform across multiple indications.

Key products, technologies and clinical programs

Ryoncil is the cornerstone. Approved by the FDA in December 2024 for paediatric patients aged two months and older with SR-aGvHD, it is the first FDA-approved MSC therapy and the only FDA-approved therapy for children under 12 with the condition. It reportedly carries a very high gross margin — around 93% per company disclosures — offering substantial operating leverage as volumes scale.

Beyond the approved paediatric indication, Mesoblast is pursuing an important label extension into adult SR-aGvHD. Because adult allogeneic transplants substantially outnumber paediatric ones, the company has indicated this could more than double the addressable graft-versus-host disease opportunity.

Revascor (rexlemestrocel-L) is Mesoblast's cardiovascular candidate. The company has signalled a biologics licence application (BLA) pathway targeting end-stage heart failure with reduced ejection fraction in patients supported by left ventricular assist devices (LVADs), focused on reducing complications such as gastrointestinal bleeding. In chronic low back pain (CLBP) linked to degenerative disc disease, Mesoblast has reported reaching its recruitment target in a pivotal Phase 3 trial — a potential blockbuster, though investigational and subject to trial outcomes.

Clinical-development position

Mesoblast now straddles commercial and clinical stages. Ryoncil is fully approved and generating revenue in paediatric SR-aGvHD. The adult SR-aGvHD extension, the Revascor heart-failure program and the CLBP Phase 3 trial are at various points of the regulatory and clinical pathway and are not approved. Investors should distinguish between Ryoncil's realised, approved revenue and the pipeline's potential value, which depends on outcomes that are not guaranteed. Cell-therapy trials carry manufacturing, consistency and endpoint risks that have historically complicated the sector.

Regulatory and commercial pathway

The regulatory story is broadly constructive. The 2024 Ryoncil approval was a landmark for the MSC field, and Mesoblast has reported continued engagement with the FDA on both the adult SR-aGvHD label extension and an accelerated-approval pathway consideration for Revascor in ischaemic heart failure. A BLA filing for Revascor has been flagged as a near-term step. None of these later-stage steps guarantees approval, and complete response letters or additional-data requests remain possible outcomes in any submission. Commercially, Ryoncil's launch is being driven through major US paediatric transplant centres, a concentrated and identifiable customer base that has supported rapid early uptake.

Latest financial position

Mesoblast's financial profile has improved materially with commercialisation. Ryoncil generated preliminary net revenue of about US$36 million in the June 2026 quarter and about US$115 million across its first full year (US dollars; preliminary/unaudited for the June quarter). Earlier, December 2025 quarter sales were about US$35.1 million (up 60% sequentially) and March 2026 quarter net revenue about US$30.3 million, illustrating the ramp.

On the balance sheet, Mesoblast reported cash of about US$130 million at 31 December 2025 and a US$125 million facility with its largest shareholder on terms it described as lower cost and not encumbering material assets or IP. As a company still investing heavily in pipeline development, its cash runway and potential funding needs remain relevant, and dilution risk cannot be excluded if additional capital is required. Ryoncil's high gross margin, however, improves the trajectory toward self-funded operations.

Market opportunity

The addressable markets are substantial. The SR-aGvHD market has been described as having annual potential exceeding US$1 billion, and adding adults could materially expand it. Heart failure and chronic low back pain are far larger populations, giving Revascor and the CLBP program blockbuster potential if they succeed. That said, addressable-market size measures opportunity, not realised value; converting it depends on regulatory approvals, reimbursement and commercial execution.

Recent official announcements

Verified developments over the past year include: FDA approval of Ryoncil for paediatric SR-aGvHD (December 2024) and commercial launch; continued FDA engagement on an adult SR-aGvHD label extension and a Revascor accelerated-approval pathway (mid-2025); half-year FY26 results showing about US$130 million cash at 31 December 2025; quarterly Ryoncil sales updates; the CLBP Phase 3 recruitment target; and the 10 July 2026 fourth-quarter update confirming about US$36 million quarterly and about US$115 million full-year Ryoncil net revenue.

Potential positive considerations

Several factors support the constructive case. Ryoncil is a first-in-class approved product with a high gross margin and a launch that has exceeded early expectations. The adult SR-aGvHD extension offers a relatively lower-risk expansion of an already-approved therapy, while Revascor and the CLBP program provide larger, riskier optionality. The US$130 million cash position and lower-cost shareholder facility improve financial flexibility. For a company long viewed as pre-revenue, demonstrated commercial traction is a meaningful de-risking event.

Main risks and uncertainties

The risks remain significant. Ryoncil revenue, while strong, is early and the June-quarter figures are preliminary and unaudited. The paediatric SR-aGvHD population is relatively small, so sustained growth depends on the adult label extension and pipeline success, neither assured. The Revascor BLA and CLBP Phase 3 trial could face negative data, complete response letters or delays. Cell-therapy manufacturing and consistency carry inherent risk. Mesoblast's history of cash burn and capital raising means dilution risk persists if further funding is needed. Competition, reimbursement pressure and US-dollar translation are additional factors. Past performance is no guide to future outcomes.

What investors may watch next

Key monitoring items: progress and timing on the adult SR-aGvHD label extension; the Revascor BLA submission and any FDA feedback; data from the chronic low back pain Phase 3 trial; audited confirmation of full-year Ryoncil revenue and FY27 growth commentary; quarterly cash burn against the reported cash position; and any further capital-management steps. Each is a potential catalyst in either direction, subject to clinical and regulatory outcomes.

Mesoblast Limited (ASX:MSB): promise meeting proof

The 6.25% surge to A$2.38 on 13 July 2026 reflects a genuine, verified catalyst: Ryoncil's first-full-year revenue of about US$115 million confirming that Mesoblast's landmark FDA approval is translating into sales. After years defined by pipeline hope, Mesoblast Limited (ASX:MSB) is beginning to be judged on commercial delivery. The adult SR-aGvHD extension, Revascor and the chronic low back pain program will determine whether this is a broader growth story or a single-product success. For investors researching ASX biotech shares, Mesoblast now offers a rare combination of realised revenue and pipeline optionality — alongside the clinical, regulatory and funding risks that accompany cell-therapy development. This article is general information only and not financial advice.